Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Pinkert Jessica"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Julian Glueck, Christoph Freiberg, Dieter Zopf, Hans-Henning Boehm, Heiner Apeler, Wolf-Dietrich Doecke, Florian Wessel, Joerg Weiske, Beckhove Philipp, Mark Trautwein, Ruprecht Zierz, Joerg Willuda, Sabine Wittemer-Rump, Pinkert Jessica, Ziegelbauer Karl, Uwe Gritzan, Yingzi Ge, Oliver von Ahsen, Bertolt Kreft, Gutierrez Eva-Maria, Sven Golfier, Rienk Offringa
Publikováno v:
Cancer Research. 78:1771-1771
CEACAM6 (CD66c) was previously shown to act as a novel immune checkpoint regulator suppressing the activity of effector T cells against tumors (Witzens-Harig et al., Blood 2013). CEACAM6 is a GPI-linked protein that is strongly expressed at the tumor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::34ee3a37f29cde47828164a13773f746
https://doi.org/10.1158/1538-7445.am2018-1771
https://doi.org/10.1158/1538-7445.am2018-1771
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Pinkert J; Joint Immunotherapeutics Laboratory of the DKFZ-Bayer Innovation Alliance, German Cancer Research Center (DKFZ), Heidelberg, Germany., Boehm HH; Joint Immunotherapeutics Laboratory of the DKFZ-Bayer Innovation Alliance, German Cancer Research Center (DKFZ), Heidelberg, Germany., Trautwein M; Pharmaceutical Division, Bayer AG, Wuppertal, Germany., Doecke WD; Pharmaceutical Division, Bayer AG, Berlin, Germany., Wessel F; Joint Immunotherapeutics Laboratory of the DKFZ-Bayer Innovation Alliance, German Cancer Research Center (DKFZ), Heidelberg, Germany., Ge Y; Joint Immunotherapeutics Laboratory of the DKFZ-Bayer Innovation Alliance, German Cancer Research Center (DKFZ), Heidelberg, Germany., Gutierrez EM; Joint Immunotherapeutics Laboratory of the DKFZ-Bayer Innovation Alliance, German Cancer Research Center (DKFZ), Heidelberg, Germany., Carretero R; Joint Immunotherapeutics Laboratory of the DKFZ-Bayer Innovation Alliance, German Cancer Research Center (DKFZ), Heidelberg, Germany., Freiberg C; Pharmaceutical Division, Bayer AG, Wuppertal, Germany., Gritzan U; Pharmaceutical Division, Bayer AG, Cologne, Germany., Luetke-Eversloh M; Pharmaceutical Division, Bayer AG, Berlin, Germany., Golfier S; Pharmaceutical Division, Bayer AG, Berlin, Germany., Von Ahsen O; Pharmaceutical Division, Bayer AG, Berlin, Germany., Volpin V; Division of Interventional Immunology, RCI Regensburg Center for Interventional Immunology, Regensburg, Germany., Sorrentino A; Division of Interventional Immunology, RCI Regensburg Center for Interventional Immunology, Regensburg, Germany., Rathinasamy A; Division of Interventional Immunology, RCI Regensburg Center for Interventional Immunology, Regensburg, Germany., Xydia M; Division of Interventional Immunology, RCI Regensburg Center for Interventional Immunology, Regensburg, Germany., Lohmayer R; Division of Interventional Immunology, RCI Regensburg Center for Interventional Immunology, Regensburg, Germany.; Institute of Theoretical Physics, University of Regensburg, Regensburg, Germany., Sax J; Division of Interventional Immunology, RCI Regensburg Center for Interventional Immunology, Regensburg, Germany., Nur-Menevse A; Division of Interventional Immunology, RCI Regensburg Center for Interventional Immunology, Regensburg, Germany., Hussein A; Division of Interventional Immunology, RCI Regensburg Center for Interventional Immunology, Regensburg, Germany., Stamova S; Division of Interventional Immunology, RCI Regensburg Center for Interventional Immunology, Regensburg, Germany., Beckmann G; Pharmaceutical Division, Bayer AG, Berlin, Germany., Glueck JM; Pharmaceutical Division, Bayer AG, Wuppertal, Germany., Schoenfeld D; Pharmaceutical Division, Bayer AG, Wuppertal, Germany., Weiske J; Pharmaceutical Division, Bayer AG, Berlin, Germany., Zopf D; Pharmaceutical Division, Bayer AG, Berlin, Germany., Offringa R; Joint Immunotherapeutics Laboratory of the DKFZ-Bayer Innovation Alliance, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Surgery, University Hospital Heidelberg, Heidelberg, Germany., Kreft B; Pharmaceutical Division, Bayer AG, Berlin, Germany., Beckhove P; Joint Immunotherapeutics Laboratory of the DKFZ-Bayer Innovation Alliance, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Division of Interventional Immunology, RCI Regensburg Center for Interventional Immunology, Regensburg, Germany.; Hematology and Oncology Department, University Hospital Regensburg, Regensburg, Germany., Willuda J; Pharmaceutical Division, Bayer AG, Berlin, Germany.
Publikováno v:
Oncoimmunology [Oncoimmunology] 2021 Dec 30; Vol. 11 (1), pp. 2008110. Date of Electronic Publication: 2021 Dec 30 (Print Publication: 2022).